Hospital Groups to CMS: Don’t Rob Some Hospitals to Repay 340B Hospitals for Your Illegal Drug Payment Cuts

AHA and NRHA
AHA and NRHA both urged the Biden administration not to claw back Medicare payments from some hospitals to pay for the remedy for illegal drug payment cuts for 340B hospitals.

Two hospital groups separately urged Biden administration officials this month to not divert funding from non-340B hospitals and some 340B hospitals in order to repay other 340B hospitals for almost five years’ worth of illegal Medicare Part B drug payment

Read More »

Health Center Invokes 340B Contract Pharmacy Ruling in Key 340B Patient Definition Federal Lawsuit

Genesis Health Care
South Carolina health center Genesis Health Care told a federal court that HRSA lacks authority to enforce its 1996 340B patient definition and misinterpreted congressional intent about who is a 340B eligible patient.

Federal health care officials can’t make a South Carolina health center obey their reading of the 340B patient definition for the same reason a federal appeals court said in January that the officials can’t force drug manufacturers to deliver 340B

Read More »

PhRMA and Bristol Myers Squibb Sue Separately To Stop Medicare Drug Price Negotiation

US District Court Austin, Texas
PhRMA filed suit in federal district court in Austin, Texas, to strike down legislation letting Medicare negotiate some drug prices.

Drug industry trade group Pharmaceutical Research and Manufacturers of America and drug manufacturer Bristol Myers Squibb have filed separate federal lawsuits to stop Medicare from negotiating the prices of some drugs, charging that it would impose unconstitutional price controls on

Read More »

U.S. Senate “Group of Six” Elaborates on Why it Wants 340B Stakeholder Input

John Thune
"It is critical that the 340B program continues to serve its original purpose of supporting health care providers as they serve the needs of South Dakota patients and communities," Sen. John Thune (R-S.D.) said about his and five fellow senators' request for public input on how to improve 340B.

The six U.S. senators who asked Friday morning for ideas on ways to improve the 340B program elaborated on their reasons why in a news release that afternoon.

Sens. John Thune (R-S.D.), Debbie Stabenow (D-Mich.), Shelley Moore Capito (R-W.Va.), Tammy

Read More »

AHA Urges HRSA to Restore Policy Allowing Earlier Use of 340B Drugs in Hospital Outpatient Clinics

AHA
The American Hospital Association published a study that found 340B hospitals' community benefit increased significantly in 2020.

The American Hospital Association has asked the U.S. Health Resources and Services Administration to resume letting hospitals dispense 340B drugs at offsite clinics that have not yet appeared on the hospital’s most recently filed Medicare cost report.

AHA asked HRSA

Read More »

MedPAC Still Backs Cutting 340B Hospitals’ Part B Drug Payments

Cancer chemotherapy
MedPAC continues to hold that Medicare should pay less for Part B drugs furnished by 340B hospitals.

The Medicare Payment Advisory Commission is sticking by its long-standing recommendation that Medicare should pay less for Part B drugs furnished by 340B hospitals.

“We continue to believe that this approach is appropriate, and the specific level of payment reduction

Read More »

340B Registration for Third Quarter of 2023 Will Run from July 1 to July 17

Registration green
Q3 2023 covered entity registration for the 340B program runs from July 1 to July 17, HRSA says.

The U.S. Health Resources and Services Administration has added two days to the next quarterly 340B registration period.

A HRSA spokesperson said Friday that Q3 registration for 340B covered entities, their child sites, and their contract pharmacies will begin July

Read More »

News Alert

Six Democratic and Republican U.S. Senators Ask 340B Stakeholders for “Bipartisan Policy Solutions”

Senate 340B RFI
A bipartisan group of six U.S. senators today sought 340B stakeholders' best advice on subjects including 340B contract pharmacy, duplicate discount prevention, accountability, and ensuring that program benefits accrue to covered entities and their patients.

Six Democratic and Republican U.S. senators this morning asked 340B drug pricing program stakeholders for input on “bipartisan policy solutions that would ensure the program has stability and oversight to continue to achieve its original intention of serving eligible patients.”

Read More »

Congressional Republicans Want to Know if 340B Plays a Role in Drug Shortages

Drug shortages
The GOP leaders of two congressional committees want public input on whether 340B program growth leads to drug shortages.

U.S. House Energy & Commerce Committee Chair Cathy McMorris Rodgers (R-Wash.) and Senate Finance Committee ranking Republican Mike Crapo (Idaho) are soliciting public input on what’s driving the increase in drug shortages, including whether or not the 340B drug pricing

Read More »

First Merck, Now Chamber of Commerce Sues to Stop Medicare Drug Price Negotiation

U.S. Chamber of Commerce
The U.S. Chamber of Commerce and local and state chambers have sued to stop Medicare from negotiating "maximum fair prices" on a small number of expensive single-source drugs.

The U.S. Chamber of Commerce and three state and local affiliates are asking a federal court to strike down the part of the Inflation Reduction Act that lets Medicare negotiate “maximum fair prices” (MFPs) for some expensive, single-source drugs, arguing

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live